Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
This UK clinical trial is exploring a new treatment called anifrolumab for adults between 18 and 70 who have moderate to severe Systemic Lupus Erythematosus (SLE), often referred to simply as lupus. The main goal is to find out if this new drug, given as an injection under the skin (subcutaneously), is both safe and effective in improving lupus symptoms when taken alongside patients' current medications. Participants will be randomly assigned to receive either anifrolumab or a placebo (a dummy drug) once a week for about a year. After this, some may continue receiving anifrolumab in an 'open-label' part of the study. This research aims to provide more options for managing lupus.
En un coup d'œil
De quoi parle cette étude ?
This study is looking into a new medication called anifrolumab as a potential new treatment for Systemic Lupus Erythematosus, or SLE. SLE is a long-term condition that causes the immune system to mistakenly attack healthy tissues, leading to inflammation and damage in various parts of the body. This trial focuses on adults in the UK who are currently living with moderate to severe SLE and are already receiving standard care, such as steroids, antimalarial drugs, or immunosuppressants.
The researchers want to see if adding anifrolumab to a patient's existing treatment plan can improve symptoms and reduce the severity of their lupus. They will also carefully monitor any side effects to make sure the treatment is safe. Participants will be randomly put into one of two groups: one group will receive anifrolumab, and the other will receive a placebo, which looks exactly like the study drug but contains no active medication. This is a common way to test new treatments fairly.
The study is planned to last over a year for each participant, with the main assessment happening after 52 weeks. After this initial period, some participants might have the option to continue receiving anifrolumab in a follow-up phase of the study. This research is important because it could lead to new ways to manage lupus, offering hope for better symptom control and quality of life for people affected by this condition.
Points clés
- This study tests a new injection, anifrolumab, for moderate to severe lupus.
- It's for adults 18-70 already on standard lupus treatment.
- Participants will get either anifrolumab or a placebo for about a year.
- The drug is given as a weekly injection under the skin.
- The study aims to check if anifrolumab is safe and effective.
- Vous pouvez vous retirer à tout moment.
Qui peut être éligible ?
To be able to take part in this study, you would need to be an adult between 18 and 70 years old with a diagnosis of Systemic Lupus Erythematosus (SLE) for at least 24 weeks. Your lupus must be considered moderate to severe, despite already taking standard lupus medications like steroids, antimalarials, or immunosuppressants. Your doctor will use specific medical scales to confirm the severity of your lupus symptoms and ensure you have particular markers in your blood related to SLE.
There are also certain reasons why you might not be able to join. For example, if you have very severe or unstable lupus affecting your brain or kidneys, or if you've had certain serious infections or cancers (other than specific skin cancers or treated cervical cancer) recently, you wouldn't be eligible. Conditions that severely weaken your immune system or certain liver conditions would also prevent participation.
The study team will carefully review your medical history to make sure that taking part is safe for you and that the study results will be clear. They will explain all the criteria in detail during the screening process.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Are you 18-70 years old?
- Do you have a diagnosis of Systemic Lupus Erythematosus (SLE)?
- Is your lupus considered moderate to severe?
- Are you currently taking standard lupus medications (e.g., steroids, antimalarials, immunosuppressants)?
- Have you spoken to your doctor about your general health and existing conditions?
En quoi consiste la participation ?
If you decide to participate, you would be involved in this study for approximately 52 weeks, with a potential to extend for an additional 52 weeks. You would be randomly assigned to receive either the study drug (anifrolumab) or a placebo (a dummy treatment) through an injection under your skin, using a pre-filled syringe. These injections would be given once a week for the first 52 weeks.
Throughout the study, you would attend regular clinic visits where the study team will monitor your health, assess your lupus symptoms, and check for any side effects. This will involve physical examinations, blood tests, and questionnaires. The study team will explain the exact schedule of visits and what each visit entails. After the initial 52 weeks, if you choose and are eligible, you might be able to enter an 'open-label' extension where everyone receives anifrolumab for up to another 52 weeks. You are free to withdraw from the study at any time.
Risques et avantages potentiels
Locations (140)
- Research SiteCode postal vérifiéBirmingham, États-Unis
- Research SiteCode postal vérifiéParadise Valley, United States
- Research SiteCode postal vérifiéPhoenix, États-Unis
- Research SiteCode postal vérifiéEl Cajon, United States
- Research SiteCode postal vérifiéFullerton, United States
- Research SiteCode postal vérifiéHemet, United States
- Research SiteCode postal vérifiéLa Mesa, United States
- Research SiteCode postal vérifiéLos Angeles, États-Unis
- Research SiteCode postal vérifiéMenifee, United States
- Research SiteCode postal vérifiéUpland, United States
- Research SiteCode postal vérifiéAurora, États-Unis
- Research SiteCode postal vérifiéBrandon, United States
Questions fréquentes
What is Systemic Lupus Erythematosus (SLE)?
SLE, or lupus, is a long-term condition where your body's immune system mistakenly attacks its own healthy tissues and organs, causing widespread inflammation and damage.
What is anifrolumab?
Anifrolumab is a new medication being studied for lupus. It's designed to help regulate the immune system. In this study, it's given as an injection under the skin.
Will I definitely get the new drug?
No, this study is 'randomised,' meaning you would have a 50/50 chance of receiving either anifrolumab or a placebo (a dummy drug) for the first year. This helps researchers compare the treatment fairly.
Combien de temps dure l'étude ?
The main part of the study lasts for about 52 weeks (one year). If eligible and you choose to, you might then be able to continue receiving anifrolumab for up to another 52 weeks in an extension period.
Que se passe-t-il si je change d'avis concernant ma participation ?
You are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care or relationship with your doctor.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.